A study coming out in the November issue of the Clinical Journal of the American Society of Nephrology is reporting that type 2 men whose blood contained a high count of eosinophils, a sign of allergic inflammation, also had albumin in their urine, which is an early indication of kidney disease. Eosinophils are white blood cells that increase in number during an allergic reaction. Albumin is a protein in the blood that helps regulate blood volume and acts as a carrier for other molecules. Albumin is not normally found in the urine, however, because when healthy kidneys filter the blood, they retain what the body needs (like proteins) and allow only smaller "impurities" into the urine. But during diabetes, too much blood sugar can damage the filtering structures of the kidneys, causing them to thicken and become scarred. Eventually, they begin to leak, and protein (albumin) begins to pass into the urine.
The U.S. Food and Drug Administration has learned that some stolen vials of the long-acting insulin Levemir made by Novo Nordisk Inc. have reappeared and are being sold in the U.S. market. Three lots or a total of 129,000 vials of this product were stolen in all. These stolen insulin vials may not have been stored and handled properly and may be dangerous for patients to use.
The FDA has announced that starting in early April, itsEndocrinologic and Metabolic Drugs Advisory Committee will begin looking into two new drugs for type 2 diabetes: saxagliptin tablets from Bristol-Meyers Squibb and liraglutide, an injection drug from Novo Nordisk.
A complex sugar derived from glucose during the body’s metabolic processes could be a way to reliably detect a pre-diabetes condition, say researchers at the Johns Hopkins University School of Medicine in Baltimore. If it does, the “biomarker” (an indicator of an organism’s state of health) could provide enough early warning that patients nearing the onset of type 2 diabetes could take steps to slow or even halt it through lifestyle changes.
DM-99, a drug under development by the Canadian drug company DiaMedica, Inc., has just finished a phase 2a "proof of concept" trial with 40 type 2 patients in Europe. Although the company did not release performance figures from the trial, it found them sufficiently encouraging to move further into phase 2 testing.
We first reported on salsalate, an aspirin-like drug discovered in the nineteenth century, last October. At that time, researchers at the Joslin Diabetes Center in Boston discovered that it appears to reduce inflammation and lower blood glucose in people with type 2 diabetes.
Two diets - one severely restricting carbohydrate intake but with no limit on calories, and the other emphasizing low-glycemic carbohydrates and low calories - allowed high percentages of obese type 2 patients in a university study to reduce or even eliminate their diabetes medications (95.2 percent of the patients on the extreme low-carb diet and 62.1 percent of the patients on the low-glycemic diet).
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.